Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (SAB BIO), whose exchange-listed warrants trade under the symbol SABSW, is a clinical-stage biopharmaceutical company that regularly issues news about its lead program SAB-142 and its broader human immunoglobulin platform. Company press releases describe SAB BIO as focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies for immune and autoimmune disorders, with a primary emphasis on autoimmune type 1 diabetes (T1D).
News coverage for SAB BIO often centers on clinical milestones for SAB-142, a multi-specific, fully human anti-thymocyte globulin in development as a potentially disease-modifying, redosable immunotherapy for Stage 3 T1D. Recent announcements include positive Phase 1 safety and pharmacodynamic data, initiation and enrollment progress in the Phase 2b SAFEGUARD trial, and presentations of SAB-142 data at major diabetes conferences such as the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the Asian Conference on Innovative Therapies for Diabetes Management.
Investors following SABSW-related news will also see updates on SAB BIO’s corporate and financial developments. The company has reported participation in healthcare investor conferences, financing transactions such as the private placement of Series B Convertible Preferred Stock and warrants, and governance updates including board appointments. SEC-related announcements, such as proxy materials for stockholder meetings to approve share issuances and equity plan amendments, are another recurring theme.
Because SAB BIO’s strategy is to advance SAB-142 as a therapy that may change the treatment paradigm for autoimmune type 1 diabetes, many news items highlight mechanistic data, safety findings, and trial design details that support this goal. For readers tracking SABSW and SAB Biotherapeutics, the news stream provides insight into clinical progress, regulatory interactions, capital structure decisions, and scientific visibility through conference presentations. Bookmarking this page allows ongoing access to company press releases and third-party coverage linked to SABSW and the underlying SAB Biotherapeutics common stock.
SAB Biotherapeutics (Nasdaq: SABS) said members of management will participate in two investor conferences in Miami Beach in March 2026: the Leerink Partners Global Healthcare Conference on March 9 at 3:00 p.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 11 at 8:30 a.m. ET.
Both appearances are in a fireside chat format. According to the company, live webcasts and archived recordings will be available in the Investors & Media section of the company website at www.sab.bio.
SAB Biotherapeutics (Nasdaq: SABS) announced that management will participate in two investor conferences in February 2026: Guggenheim Securities Emerging Outlook: Biotech Summit on February 11, 2026 (10:30 a.m. ET, New York) and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 (8:40 a.m. ET, virtual).
According to the company, both appearances include fireside chats and will be available live and on demand via the Investors & Media section of the company website at www.sab.bio.
SAB BIO (Nasdaq: SABS) announced two board appointments effective January 7, 2026: David Zaccardelli, Pharm.D. as Chair of the Board and Rita Jain, M.D. as an independent director.
Management highlights Zaccardelli's 20+ years of biopharma leadership and his role in the successful launch of Ohtuvayre, and describes Jain's two decades of experience in autoimmune and inflammatory disease drug development. Both appointees are presented as bringing complementary expertise to support clinical execution and advancement of SAB-142, the company's fully human anti-thymocyte immunoglobulin candidate for type 1 diabetes and other autoimmune diseases.
SAB Biotherapeutics (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco.
A live webcast will be available in the Investors section of the company website at www.sab.bio, and an archived replay will be posted for approximately 30 days after the presentation.
SAB BIO (Nasdaq: SABS) announced the first patient was dosed with SAB-142 in the Phase 2b registrational SAFEGUARD trial on Dec 18, 2025. The trial targets stage 3 type 1 diabetes using a fully human anti-thymocyte immunoglobulin intended as a disease-modifying therapy. Enrollment is ongoing at multiple global sites, including the U.S., Australia, and New Zealand, with European sites joining soon. The company plans to share Phase 2b data in 2H 2027.
SAB BIO (Nasdaq: SABS) announced positive confirmatory Phase 1 results for SAB-142, an hATG candidate for stage 3 type 1 diabetes (T1D). In 68 treated participants (healthy volunteers and T1D patients), SAB-142 showed 0% serum sickness (0/68), 0% anti-drug antibody events (0/68), no drug-related serious adverse events, and transient lymphopenia that resolved to baseline within 1–3 days in 100% of subjects (68/68). Most adverse events were mild and infusion-related. A registrational Phase 2b SAFEGUARD trial is underway and recruiting globally, with the company on track to dose the first patient by year-end.
SAB BIO (Nasdaq: SABS) will present clinical data on SAB-142 at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia), December 9-11, 2025 in Singapore. Presentations on December 10, 2025 highlight Phase 1 results reporting a multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile without serum sickness or anti-drug antibodies at the target dose.
The company said it is currently in Phase 2b development for delaying progression of new-onset Stage 3 type 1 diabetes and expects to report additional Phase 1 data and dose the first Phase 2b SAFEGUARD patient later in 2025. Presentations will be posted on the company website.
SAB BIO (Nasdaq: SABS) initiated its registrational Phase 2b SAFEGUARD trial of lead candidate SAB-142 in new-onset Stage 3 T1D, activated multiple sites in the US, Australia and New Zealand, and is on-track to dose the first patient by year-end 2025. The company reported a strong cash position of $161.5 million at Sept 30, 2025 (vs. $20.8 million at Dec 31, 2024) and said its runway extends through 2028. Phase 1 data presented at EASD and ISPAD showed a favorable safety profile, no serum sickness or anti-drug antibodies at the target dose, and sustained immunomodulation. Financials: Q3 R&D $9.0M, other income $58.1M, and Q3 net income $45.4M. Company expects SAFEGUARD data in 2H 2027 and to present additional Phase 1 redosing data by year-end 2025.
SAb Biotherapeutics (Nasdaq: SABS) will present clinical and translational data for its lead program SAB-142 at the 51st ISPAD Annual Conference in Montréal, Nov 5–8, 2025.
Six presentations (four oral, two posters) describe Phase 1 results showing a multi-specific mechanism of action with sustained immunomodulation, a favorable safety profile at target dose without serum sickness or anti-drug antibodies, and a novel pharmacokinetic assay for measuring SAB-142.
The presentations cover specimen quality methods, binding specificity profiling, immunomodulation without sustained lymphodepletion, mechanism of action, PK assay details, and safety findings, led by SAB BIO scientific and clinical leaders.
SAb Biotherapeutics (Nasdaq: SABS) announced that members of management will participate in three investor conferences in November–December 2025: a UBS Global Healthcare Conference fireside chat on Nov 10, 2025 at 2:45 p.m. ET in West Palm Beach, a Guggenheim Healthcare Innovation Conference fireside chat on Nov 12, 2025 at 10:00 a.m. ET in Boston, and an Evercore Healthcare Conference fireside chat on Dec 2, 2025 at 3:50 p.m. ET in Coral Gables.
Live webcasts and archived recordings will be available on the company Investor Relations Events page at www.sab.bio.